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You say you want a (melanoma) 
revolution
Once treated only palliatively, metastatic melanoma can 
now be treated with potentially curative intent. In the past 
three years, the US Food and Drug Administration has 
approved five drugs to treat advanced melanoma, and sev-
eral more are in the pipeline. In a review, Lo and Fisher 
describe our current understanding of melanoma risk fac-
tors and offer insight into advancements in melanoma treat-
ment. Although targeted inhibition of both BRAF and MEK 
stabilizes disease, resistance to treatment almost inevita-
bly occurs, suggesting that treatments that counteract this 
resistance are crucial. Furthermore, melanoma immuno-
therapies, such as autologous T cells and immune check-
point inhibition with ipilimumab and pembrolizumab, 
have begun to achieve clinical success. Newly discovered 
drugs as well as combinations of immune checkpoint inhi-
bition and BRAF/MEK inhibition offer promising treatment 
options. Deep-sequencing projects, which will illuminate 
genomic and epigenomic alterations in melanoma devel-
opment as well as in treatment resistance, will undoubt-
edly fuel these advancements. (Science 346:945–9, 2014) 
Selected by B. Gilchrest
Which antihistamine?
H1 antihistamines are the mainstay for treating chronic 
spontaneous urticaria (CSU), which by nature occurs in an 
unprovoked setting and lasts for at least six weeks. In an 
attempt to determine which specific H1 antihistamines are 
effective and safe for treating CSU, Sharma and colleagues 
conducted a review of 73 randomized controlled studies 
containing 9,759 participants. Overall, the examined anti-
histamines (e.g., cetirizine, desloratadine, and levocetiri-
zine) worked at reasonable doses, but no single histamine 
appeared to be superior, although the quality of the evi-
dence for the majority of the outcomes was low. A lack of 
head-to-head comparisons for these treatments, however, 
prevented the recommendation of a single antihistamine, 
highlighting the need for additional well-designed compara-
tive studies. (Cochrane Database Syst Rev, published online 
14 November 2014; doi:10.1002/14651858.CD006137.
pub2) Selected by H. Williams
Personal stem cell therapy for RDEB
Autosomal recessive dystrophic epidermolysis bullosa 
(RDEB) is a particularly disabling blistering disease without 
any available cure, although cell therapy offers the potential 
for treatment. On the heels of the development of COL7A1-
expressing retrovirally infected human epithelial sheets 
and the description of the generation of induced pluripo-
tent stem cells (iPSCs), three independent reports of iPSC-
based therapies for bullous skin disorders were published 
together in Science Translational Medicine. Sebastiano and 
colleagues reported human COL7A1–corrected iPSCs with 
great therapeutic promise. These investigators demonstrated 
the derivation of iPSCs from RDEB patients via good man-
ufacturing procedures followed by highly efficient repair 
of the disease-causing mutation in the COL7A1 locus via 
an adeno-associated viral approach. These cells were dif-
ferentiated into keratinocytes that were stratifying and 
graftable and produced wild-type type VII collagen. The 
keratinocytes, which were screened to exclude the presence 
of any genes associated with squamous cell carcinoma, 
were capable of regenerating healthy skin tissue in mice, 
underscoring the attractiveness of these newly described 
cells for RDEB treatment. (Sci Transl Med 6:264ra163, 
2014) Selected by M. Amagai
Covering the wounds
In a recent review of the current experimental approaches to 
treating cutaneous wounds, Sun and colleagues emphasized 
advances in skin grafting, bioengineered skin equivalents, 
and cell-based skin therapies. Skin grafting, although imper-
fect in all its forms, can successfully serve as temporary bio-
logic dressings to limit infections, reduce substrate loss, and 
improve survival for victims of burns and difficult wounds. 
Because nonautologous grafts undergo rejection, transplant-
able bioengineered skin has found success in clinical use. 
Furthermore, stem cell–based therapies using mesenchymal 
stroma/stem cells, adipose tissue–derived stem cells, and 
induced pluripotent stem cells are undergoing development 
for cutaneous wound treatment. (Science 346:941–5, 2014) 
Selected by B. Gilchrest
For strong teeth and hair
Tooth enamel, which protects the teeth from dental car-
ies, contains a high mineral content as well as organic 
material. Although tooth and hair morphogenesis share 
common molecular pathways, the end results are quite 
different, and the protein composition of tooth enamel has 
not yet been completely described. Duverger and colleagues 
recently demonstrated that epithelial hair keratins, including 
KRT75, are critical structural components of human enamel. 
Data from 386 children and 706 adults revealed that hair 
disorder–associated polymorphisms in the KRT75 gene are 
linked to increased susceptibility to dental defects and car-
ies. Structural analysis of human enamel that harbored these 
polymorphisms suggested that epithelial hair keratins sta-
bilize enamel tufts and rod sheaths in a manner similar to 
their role in the hair shaft. Thus, KRT75 is a new addition 
to the list of enamel formation genes, which include ame-
logenin, ameloblastin, enamelin, and tuftelin. (J Clin Invest 
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